D Carmody1, K L Lindauer1, R N Naylor1. 1. Departments of Medicine and Pediatrics, Section of Adult and Pediatric Endocrinology, Diabetes, & Metabolism, University of Chicago, Illinois, USA.
Abstract
BACKGROUND: Glucokinase related maturity-onset diabetes of the young (GCK-MODY) is a form of monogenic diabetes characterized by mildly elevated fasting blood sugars and HbA(1c) typically ranging from 38 to 60 mmol/mol (5.6-7.6%). It is frequently unrecognized or misdiagnosed as Type 1 or Type 2 diabetes, resulting in unnecessary pharmacologic therapy. CASE REPORT: Two brothers were initially diagnosed with Type 1 diabetes mellitus. The brothers were maintained on a total daily insulin dose of 0.3-0.5 units/kg/day and had HbA(1c) values of 40-51 mmol/mol (5.8-6.8%) throughout childhood. After over 10 years of insulin treatment, the younger brother chose to discontinue his insulin therapy without informing his family or his clinician. Following cessation of insulin treatment, he did not experience any change in overall glycaemic control. Subsequent research-based genetic testing revealed a deleterious mutation in GCK in both brothers (p.Val182Met). The older brother subsequently discontinued insulin therapy and both have remained off all pharmacological therapy with good glycaemic control (HbA(1c) < 53 mmol/mol, < 7%) and no adverse complications. The family was advised to seek confirmatory genetic testing in the father and other relatives with hyperglycaemia. CONCLUSION: The family described above exemplifies the rationale behind considering a genetic cause when evaluating every person with new-onset hyperglycaemia or those with atypical diabetes. The cost of genetic testing for the most common MODY causing genes may be offset by savings made in therapeutic costs. It is important that all clinicians supervising diabetes care recognize the cardinal features that distinguish GCK-MODY from other forms of diabetes.
BACKGROUND:Glucokinase related maturity-onset diabetes of the young (GCK-MODY) is a form of monogenic diabetes characterized by mildly elevated fasting blood sugars and HbA(1c) typically ranging from 38 to 60 mmol/mol (5.6-7.6%). It is frequently unrecognized or misdiagnosed as Type 1 or Type 2 diabetes, resulting in unnecessary pharmacologic therapy. CASE REPORT: Two brothers were initially diagnosed with Type 1 diabetes mellitus. The brothers were maintained on a total daily insulin dose of 0.3-0.5 units/kg/day and had HbA(1c) values of 40-51 mmol/mol (5.8-6.8%) throughout childhood. After over 10 years of insulin treatment, the younger brother chose to discontinue his insulin therapy without informing his family or his clinician. Following cessation of insulin treatment, he did not experience any change in overall glycaemic control. Subsequent research-based genetic testing revealed a deleterious mutation in GCK in both brothers (p.Val182Met). The older brother subsequently discontinued insulin therapy and both have remained off all pharmacological therapy with good glycaemic control (HbA(1c) < 53 mmol/mol, < 7%) and no adverse complications. The family was advised to seek confirmatory genetic testing in the father and other relatives with hyperglycaemia. CONCLUSION: The family described above exemplifies the rationale behind considering a genetic cause when evaluating every person with new-onset hyperglycaemia or those with atypical diabetes. The cost of genetic testing for the most common MODY causing genes may be offset by savings made in therapeutic costs. It is important that all clinicians supervising diabetes care recognize the cardinal features that distinguish GCK-MODY from other forms of diabetes.
Authors: C C Patterson; E Gyürüs; J Rosenbauer; O Cinek; A Neu; E Schober; R C Parslow; G Joner; J Svensson; C Castell; P J Bingley; E Schoenle; P Jarosz-Chobot; B Urbonaité; U Rothe; C Krzisnik; C Ionescu-Tirgoviste; I Weets; M Kocova; G Stipancic; M Samardzic; C E de Beaufort; A Green; G G Dahlquist; G Soltész Journal: Diabetologia Date: 2012-05-26 Impact factor: 10.122
Authors: N Vionnet; M Stoffel; J Takeda; K Yasuda; G I Bell; H Zouali; S Lesage; G Velho; F Iris; P Passa Journal: Nature Date: 1992-04-23 Impact factor: 49.962
Authors: Ali J Chakera; Gill Spyer; Nicola Vincent; Sian Ellard; Andrew T Hattersley; Fidelma P Dunne Journal: Diabetes Care Date: 2014-02-18 Impact factor: 19.112
Authors: Catherine Pihoker; Lisa K Gilliam; Sian Ellard; Dana Dabelea; Cralen Davis; Lawrence M Dolan; Carla J Greenbaum; Giuseppina Imperatore; Jean M Lawrence; Santica M Marcovina; Elizabeth Mayer-Davis; Beatriz L Rodriguez; Andrea K Steck; Desmond E Williams; Andrew T Hattersley Journal: J Clin Endocrinol Metab Date: 2013-06-14 Impact factor: 5.958
Authors: Rachel E J Besser; Maggie H Shepherd; Timothy J McDonald; Beverley M Shields; Bridget A Knight; Sian Ellard; Andrew T Hattersley Journal: Diabetes Care Date: 2011-02 Impact factor: 19.112
Authors: Rochelle N Naylor; Priya M John; Aaron N Winn; David Carmody; Siri Atma W Greeley; Louis H Philipson; Graeme I Bell; Elbert S Huang Journal: Diabetes Care Date: 2013-09-11 Impact factor: 19.112
Authors: Anna M Steele; Beverley M Shields; Kirsty J Wensley; Kevin Colclough; Sian Ellard; Andrew T Hattersley Journal: JAMA Date: 2014-01-15 Impact factor: 56.272
Authors: Amanda Stride; Beverley Shields; Olivia Gill-Carey; Ali J Chakera; Kevin Colclough; Sian Ellard; Andrew T Hattersley Journal: Diabetologia Date: 2013-10-04 Impact factor: 10.122
Authors: Maggie Shepherd; Beverley Shields; Suzanne Hammersley; Michelle Hudson; Timothy J McDonald; Kevin Colclough; Richard A Oram; Bridget Knight; Christopher Hyde; Julian Cox; Katherine Mallam; Christopher Moudiotis; Rebecca Smith; Barbara Fraser; Simon Robertson; Stephen Greene; Sian Ellard; Ewan R Pearson; Andrew T Hattersley Journal: Diabetes Care Date: 2016-06-06 Impact factor: 19.112
Authors: Maggie H Shepherd; Beverley M Shields; Michelle Hudson; Ewan R Pearson; Christopher Hyde; Sian Ellard; Andrew T Hattersley; Kashyap A Patel Journal: Diabetologia Date: 2018-09-18 Impact factor: 10.122